450 related articles for article (PubMed ID: 8630957)
41. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
42. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
43. Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.
Mommers EC; Leonhart AM; von Mensdorff-Pouilly S; Schol DJ; Hilgers J; Meijer CJ; Baak JP; van Diest PJ
Int J Cancer; 1999 Oct; 84(5):466-9. PubMed ID: 10502721
[TBL] [Abstract][Full Text] [Related]
44. Impact of AdipoR1 expression on breast cancer development.
Pfeiler G; Hudelist G; Wülfing P; Mattsson B; Königsberg R; Kubista E; Singer CF
Gynecol Oncol; 2010 Apr; 117(1):134-8. PubMed ID: 20071013
[TBL] [Abstract][Full Text] [Related]
45. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Wykoff CC; Beasley N; Watson PH; Campo L; Chia SK; English R; Pastorek J; Sly WS; Ratcliffe P; Harris AL
Am J Pathol; 2001 Mar; 158(3):1011-9. PubMed ID: 11238049
[TBL] [Abstract][Full Text] [Related]
46. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Lightfoot HM; Lark A; Livasy CA; Moore DT; Cowan D; Dressler L; Craven RJ; Cance WG
Breast Cancer Res Treat; 2004 Nov; 88(2):109-16. PubMed ID: 15564794
[TBL] [Abstract][Full Text] [Related]
48. Biological profile of in situ breast cancer investigated by immunohistochemical technique.
Albonico G; Querzoli P; Ferretti S; Rinaldi R; Nenci I
Cancer Detect Prev; 1998; 22(4):313-8. PubMed ID: 9674874
[TBL] [Abstract][Full Text] [Related]
49. Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Kim HJ; Jung WH; Kim DY; Lee HD
Yonsei Med J; 2000 Jun; 41(3):345-53. PubMed ID: 10957889
[TBL] [Abstract][Full Text] [Related]
50. Incidental atypical proliferative lesions in reduction mammoplasty specimens: analysis of 2498 cases from 2 tertiary women's health centers.
Desouki MM; Li Z; Hameed O; Fadare O; Zhao C
Hum Pathol; 2013 Sep; 44(9):1877-81. PubMed ID: 23656973
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Facina G; Lopes-Costa PV; Dos Santos AR; De Vasconcelos-Valença RJ; Pinho-Sobral AL; Ferreira-Filho CP; Alencar AP; Gebrim LH; Da Silva BB
Diagn Cytopathol; 2010 Apr; 38(4):235-8. PubMed ID: 19790246
[TBL] [Abstract][Full Text] [Related]
52. Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones.
Dabiri S; Talebi A; Shahryari J; Meymandi MS; Safizadeh H
Arch Iran Med; 2013 Feb; 16(2):93-9. PubMed ID: 23360631
[TBL] [Abstract][Full Text] [Related]
53. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study.
Umekita Y; Takasaki T; Yoshida H
Virchows Arch; 1994; 424(5):491-4. PubMed ID: 7913368
[TBL] [Abstract][Full Text] [Related]
54. Benign, preinvasive and invasive ductal breast lesions. A comparative study with quantitative techniques: morphometry, image- and flow cytometry.
Ruiz A; Almenar S; Callaghan RC; Llombart-Bosch A
Pathol Res Pract; 1999; 195(11):741-6. PubMed ID: 10605693
[TBL] [Abstract][Full Text] [Related]
55. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
56. G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer.
Tuszynski GP; Rothman VL; Zheng X; Gutu M; Zhang X; Chang F
Exp Mol Pathol; 2011 Oct; 91(2):608-13. PubMed ID: 21791203
[TBL] [Abstract][Full Text] [Related]
57. Differences and Relationships Between Normal and Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Invasive Ductal Carcinoma Tissues in the Breast Based on Raman Spectroscopy.
Han B; Du Y; Fu T; Fan Z; Xu S; Hu C; Bi L; Gao T; Zhang H; Xu W
Appl Spectrosc; 2017 Feb; 71(2):300-307. PubMed ID: 28181469
[TBL] [Abstract][Full Text] [Related]
58. Fine-needle aspiration cytology of ductal hyperplasia with and without atypia and ductal carcinoma in situ.
Sneige N; Staerkel GA
Hum Pathol; 1994 May; 25(5):485-92. PubMed ID: 8200642
[TBL] [Abstract][Full Text] [Related]
59. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
Abdel-Fatah TM; Powe DG; Hodi Z; Lee AH; Reis-Filho JS; Ellis IO
Am J Surg Pathol; 2007 Mar; 31(3):417-26. PubMed ID: 17325484
[TBL] [Abstract][Full Text] [Related]
60. Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression.
Ellsworth RE; Ellsworth DL; Weyandt JD; Fantacone-Campbell JL; Deyarmin B; Hooke JA; Shriver CD
Ann Surg Oncol; 2010 Jun; 17(6):1688-94. PubMed ID: 20107913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
